Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

36.90 +2.72 (+7.96%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Definium Therapeutics, Inc. - Common Shares

< Previous 1 2 Next >

Definium Therapeutics Announces New Employee Inducement Grants

September 28, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

September 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

September 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

September 13, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

September 10, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

September 08, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

August 31, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

August 26, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

August 17, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

August 12, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 06, 2026

From Definium Therapeutics, Inc.

Via Business Wire

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

August 05, 2026

Issued on behalf of Helus Pharma (Nasdaq: HELP)

From USA News Group

Via GlobeNewswire

Definium Therapeutics Announces New Employee Inducement Grants

August 03, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

July 20, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

July 16, 2026

From Definium Therapeutics, Inc.

Via Business Wire

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)

July 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

July 06, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

June 30, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

June 30, 2026

Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity

From MarketNewsUpdates.com

Via GlobeNewswire

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

June 25, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

June 23, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics, Inc. Announces Proposed Public Offering

June 22, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder

June 22, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

June 21, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

June 15, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

June 01, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 21, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

May 12, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

May 11, 2026

From Definium Therapeutics, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.